May 13, 2021 | Press Releases
MARLBOROUGH, Mass., May 13, 2021 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...
May 11, 2021 | Press Releases
Data provide proof-of-concept for the application of INTASYL compounds as a way to unlock the potential of CAR-T cell therapy in solid tumorsData presented at the 24th Annual Meeting of the American Society of Gene & Cell TherapyMARLBOROUGH, Mass., May 11, 2021...
Apr 29, 2021 | Press Releases
MARLBOROUGH, Mass., April 29, 2021 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...
Apr 10, 2021 | Press Releases
Data presented at the AACR Annual Meeting 2021MARLBOROUGH, Mass., April 10, 2021 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi...
Mar 25, 2021 | Press Releases
MARLBOROUGH, Mass., March 25, 2021 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...
Mar 11, 2021 | Press Releases
MARLBOROUGH, Mass., March 11, 2021 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...